摘要
目的评价单次奥马珠单抗注射后行冲击脱敏治疗轻中度过敏性哮喘的疗效及安全性。方法67例轻中度过敏性哮喘患者,27例单次奥马珠单抗注射后行冲击脱敏治疗(联合组),40例仅行冲击脱敏治疗(对照组),之后行每4周1次的维持脱敏。记录冲击脱敏阶段不良反应的发生情况,维持脱敏至第16周时患者的症状、药物评分及肺功能指标等。结果联合组冲击脱敏峰值浓度完成率100%,冲击阶段全身不良反应发生率2.38%(9/378);对照组冲击脱敏峰值浓度完成率80%,冲击阶段全身反应发生率5.18%(29/560)。联合组冲击脱敏峰值浓度完成率高于对照组,冲击阶段不良反应发生率低于对照组,差异均有统计学意义(P<0.05)。维持脱敏至第16周时,对比两组的症状ACT评分、药物用量评分、FEV_(1)%、FEV_(1)/FVC、FeNO,均无显著差异(P>0.05),但较治疗前均有明显改善(P<0.05)。结论单次奥马珠单抗注射后行冲击脱敏,可显著降低冲击阶段的不良反应,提高冲击脱敏的完成率,同时保障了冲击脱敏后续的临床疗效。
Objective To evaluate the efficacy and safety of pulse desensitization after a single omalizumab injection in the treatment of mild to moderate allergic asthma.Methods Among 67 patients with mild to moderate allergic asthma,27 patients received pulse desensitization therapy after a single omalizumab injection(combination group),40 patients only received pulse desensitization therapy(control group),and then maintenance desensitization was performed every 4 weeks.The occurrence of adverse reactions during the shock desensitization phase was recorded,and the patient′s symptoms,drug scores,and pulmonary function indexes were maintained until the 16th week of desensitization.Results The completion rate of peak pulse desensitization concentration in the combination group was 100%,and the incidence of systemic adverse reactions in the shock stage was 2.38%(9/378);in the control group,the completion rate of peak pulse desensitization concentration was 80%,and the incidence of systemic reactions in the shock stage was 5.18%(29/560).The completion rate of the peak concentration of shock desensitization in the combination group was higher than that in the control group,and the incidence of adverse reactions in the shock stage was lower than that in the control group,with statistical significance(P<0.05).When desensitization was maintained until the 16th week,there was no significant difference in symptom ACT score,drug dosage score,FEV_(1)%,FEV_(1)/FVC,and FeNO between the two groups(P>0.05),but were significantly improved compared with those before treatment(P<0.05).Conclusion Shock desensitization after a single omalizumab injection can significantly reduce adverse reactions in the shock stage,improve the completion rate of shock desensitization,and ensure the subsequent clinical efficacy of shock desensitization.
作者
张文超
杜文锦
王思勤
金源曦
张秋兴
ZHANG Wen-chao;DU Wen-jin;WANG Si-qin;JIN Yuan-xi;ZHANG Qiu-xing(Department of Allergy,Henan Provincial People′s Hospital/Zhengzhou University People′s Hospital,Zhengzhou,Henan 450003,China;Department of Respiratory and Critical Care Medicine,Henan Provincial People′s Hospital/Zhengzhou University People′s Hospital,Zhengzhou,Henan 450003,China)
出处
《临床肺科杂志》
2022年第11期1634-1638,共5页
Journal of Clinical Pulmonary Medicine
